Human experience and efficacy of omidenepag isopropyl (Eybelis®; Omlonti®): Discovery to approval of the novel non-prostaglandin EP2-receptor-selective agonist ocular hypotensive drug-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Human experience and efficacy of omidenepag isopropyl (Eybelis®; Omlonti®): Discovery to approval of the novel non-prostaglandin EP2-receptor-selective agonist ocular hypotensive drug

Published:2024-02 Issue: Volume:74 Page:102426
ISSN:1471-4892
Container-title:Current Opinion in Pharmacology
language:en
Short-container-title:Current Opinion in Pharmacology

Author:

Sharif Najam A.

Publisher

Elsevier BV

Reference76 articles.

1. Glaucoma;Quigley;Lancet,2011

2. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis;Tham;Ophthalmol Times,2014

3. The pathophysiology and treatment of glaucoma: a review;Weinreb;JAMA,2014

4. Time trends, associations and prevalence of blindness and vision loss due to glaucoma: an analysis of observational data from the Global Burden of Disease Study 2017;Sun;BMJ Open,2022

5. Emerging drugs for the treatment of glaucoma: a review of phase II & III trials;Kaplan;Expet Opin Emerg Drugs,2022

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A comprehensive review of new small molecule drugs approved by the FDA in 2022: Advance and prospect;European Journal of Medicinal Chemistry;2024-11

2. TRPV4 subserves physiological and pathological elevations in intraocular pressure;2024-07-12

3. Activation of the PGE2–EP2 pathway as a potential drug target for treating eosinophilic rhinosinusitis;Frontiers in Immunology;2024-07-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP